Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
• By Emily Hayes
Bristol is developing many new immuno-oncology mechanisms, some of which were showcased at the SITC meeting in November. • Source: Bristol-Myers Squibb
Keep up with the top pharma business news of the week. On the go.
